Search

International audience

The Palaeolithic record of Greece remains highly fragmented and discontinuous in both space and time. Nevertheless, new surveys and excavations, along with the revisiting of known sites or old collections, and the conduction of lithic and faunal laboratory analyses, have altogether enriched the Greek Palaeolithic dataset with important new evidence and novel interpretations. The goal of this paper is threefold: 1) to critically review the most important aspects of the Greek Pleistocene archaeological record, from the Lower to the Upper Palaeolithic; 2) to provide a synthesis of current knowledge about the Palaeolithic of Greece and in the framework of broader discussions in human evolution research; and 3) to put in prospect the Greek record by addressing a research agenda for the future. The review of the evidence shows that Palaeolithic research in Greece has expanded its focus not only geographically but also temporally: it now includes investigations at previously under-studied areas, such as the insular settings of the Aegean and Ionian Seas, as well as formerly overlooked targets, such as Lower Palaeolithic open-air sites. The synthesis and discussion which follows offers a state-of-the-art perspective on how the primary Palaeolithic data can be assessed within local or regional geomorphic, paleoenvironmental and chronological contexts; here, our focus is on spatio-temporal discontinuities, trends in subsistence strategies and lithic technology, as well as potentially emerging biogeographical patterns. Finally, we highlight the complex topography and mosaic landscapes of the Greek peninsula in order to address two major themes for a future research agenda: the potential role of Greece as a glacial refugium, and how the Greek record could contribute to our knowledge of early hominin mobility patterns.

International audience

Yasser Abdel Kader,1 Thierry Le Chevalier,2 Tamer El-Nahas,1 Amr Sakr11Department of Clinical Oncology, Cairo University, Cairo, Egypt; 2Department of Medical Oncology, Institut Gustave Roussy, Villejuif, Paris, FrancePurpose: The majority of Egyptian patients with lung cancer present at a late stage of the disease. Bevacizumab/carboplatin/paclitaxel, as well as cisplatin plus pemetrexed, are both standard regimens for advanced non-squamous bronchogenic cancer. This study compares both regimens, in terms of efficacy and toxicity profile, in Egyptian patients.Patients and methods: This is a randomized Phase II study comparing toxicity profile and survival in 41 chemotherapy-naïve patients with stage IIIB or IV non-squamous NSCLC, with an ECOG performance status of 0 to 2. The epidermal growth factor receptor (EGFR) mutation detection was performed prior to treatment of all patients. Patients in the first group received: bevacizumab 7.5 mg/m2 on Day 1 and Day 15; carboplatin area under the curve-5 on Day 1; and paclitaxel 60 mg/m2 on Day 1, Day 8, and Day 15 every 4 weeks. In the second group, patients received cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 every 3 weeks.Results: The combination of bevacizumab/carboplatin/paclitaxel demonstrated higher Grade III–IV toxicity than cisplatin/pemetrexed regarding sensory/motor neuropathy (P = 0.06), DVT (P = 0.23), proteinuria (P = 0.23), and hypertension (P = 0.11), as well as Grade II alopecia (P = 0.001); however, no significant difference in toxicities between both arms was recorded regarding nausea and vomiting (P = 0.66), hematological toxicity, febrile neutropenia (P = 1) and fatigue (P = 0.66). Progression-free survival was similar for both treatment arms with a median of 6 months (P = 0.978). Overall median survival was comparable in both arms, 16.07 months versus 16.01 months (P = 0.89).Conclusion: Bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed provided meaningful and comparable efficacy in advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. No significant difference in toxicity was observed between both treatment arms, apart from bevacizumab/carboplatin/paclitaxel-related risks as DVT, hypertension, proteinuria, sensory/motor neuropathy, and alopecia.Keywords: bevacizumab, non-small cell lung cancer, NSCLC, pemetrexed

International audience

International audience